Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Irinotecan and Temozolomide for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy

NCT03359005 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT03359005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03359005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Irinotecan and Temozolomide for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
February 7, 2018
Completion date
February 28, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma